News Center

News Center

Shengshi Taikang Announces Completion of Nearly 100 Million RMB in Series A Funding on "Double 12"

Shengshi Taikang Announces Completion of Nearly 100 Million RMB in Series A Funding on "Double 12"

On December 12, Shengshi Taikang Biopharmaceutical Technology (Suzhou) Co., Ltd. announced at its financing press conference that it has successfully closed a nearly 100-million-RMB Series A funding round. The round was co-led by Yipu Capital and Tongren Boda, with participation from Qianrong Capital and Yida Capital. Shengshi Taikang plans to allocate the new funds toward clinical trials for two key products, including an innovative Class 1 drug, while also expanding its R&D and regulatory teams. Additionally, the company aims to further diversify its product pipeline and accelerate the advancement of upcoming new drug projects into clinical stages. Zhang Dongchi, Director of Suzhou Science and Technology Bureau, attended the event and witnessed the milestone.

Time：2017-12-12 08:39

Shengshi Taikang's Class 1 innovative drug, phosphate senglitagliptin, enters Phase I clinical trials.

Shengshi Taikang's Class 1 innovative drug, phosphate senglitagliptin, enters Phase I clinical trials.

China is a global leader in diabetes, currently home to over 100 million people living with the condition. In May 2017, Shengshi Taikang Biopharmaceutical Technology (Suzhou) Co., Ltd. received approval from the National Medical Products Administration to initiate clinical trials for its Class 1 innovative drug, phosphate sengliflozin, intended for the treatment of type 2 diabetes. Currently, Shengshi Taikang has partnered with institutions such as Jiangsu Provincial People’s Hospital to conduct Phase I clinical trials of phosphate sengliflozin. As a DPP-4 inhibitor, this drug stands out for its ability to avoid hypoglycemia and weight gain, while also offering cardiovascular protection. Moreover, given that Chinese patients with type 2 diabetes often experience more severe damage to their pancreatic beta cells compared to those in Europe and North America—yet another reason why DPP-4 inhibitors, which help restore beta-cell function, are particularly beneficial for Chinese patients—these medications are increasingly gaining recognition among physicians in China.

Time：2017-09-15 08:39

< 1...5678 >
中企跨境-全域组件 制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地